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Background: The ability to undertake controlled human malaria infection (CHMI) studies for preliminary evaluation
of malaria vaccine candidates and anti-malaria drug efficacy has been limited by the need for access to sporozoite
infected mosquitoes, aseptic, purified, cryopreserved sporozoites or blood-stage malaria parasites derived ex vivo
from malaria infected individuals. Three different strategies are described for the manufacture of clinical grade
cultured malaria cell banks suitable for use in CHMI studies.
Methods: Good Manufacturing Practices (GMP)-grade Plasmodium falciparum NF54, clinically isolated 3D7, and
research-grade P. falciparum 7G8 blood-stage malaria parasites were cultured separately in GMP-compliant facilities
using screened blood components and then cryopreserved to produce three P. falciparum blood-stage malaria cell
banks. These cell banks were evaluated according to specific criteria (parasitaemia, identity, viability, sterility, presence
of endotoxin, presence of mycoplasma or other viral agents and in vitro anti-malarial drug sensitivity of the cell bank
malaria parasites) to ensure they met the criteria to permit product release according to GMP requirements.
Results: The P. falciparum NF54, 3D7 and 7G8 cell banks consisted of >78% ring stage parasites with a ring stage
parasitaemia of >1.4%. Parasites were viable in vitro following thawing. The cell banks were free from contamination
with bacteria, mycoplasma and a broad panel of viruses. The P. falciparum NF54, 3D7 and 7G8 parasites exhibited
differential anti-malarial drug susceptibilities. The P. falciparum NF54 and 3D7 parasites were susceptible to all
anti-malaria compounds tested, whereas the P. falciparum 7G8 parasites were resistant/had decreased susceptibility
to four compounds. Following testing, all defined release criteria were met and the P. falciparum cell banks were
deemed suitable for release. Ethical approval has been obtained for administration to human volunteers.
Conclusions: The production of cultured P. falciparum blood-stage malaria cell banks represents a suitable approach
for the generation of material suitable for CHMI studies. A key feature of this culture-based approach is the ability to
take research-grade material through to a product suitable for administration in clinical trials.
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Significant advances have been made in the control of
malaria, yet half of the world’s population remains at risk.
In 2012, there were over 200 million cases of malaria and
627,000 malaria-attributable deaths, highlighting the need
for continued development of malaria control strategies
[1]. Sustainable malaria vaccine and drug development
requires access to reliable systems, such as controlled
human malaria infections (CHMIs), in which to obtain
preliminary human efficacy data to enable the selection
of candidates for further evaluation in malaria endemic
countries. Additionally, these systems can facilitate the in-
vestigation of immunological responses that are induced
in response to malaria infection [2-4].
CHMI designed to assess vaccine candidates and anti-
malaria drugs in malaria-naïve volunteers have predom-
inantly utilized experimental malaria infections induced
either by feeding laboratory-reared Plasmodium falciparum-
infected mosquitoes on study participants [5-8] or inject-
ing erythrocytes containing blood-stage malaria parasites
[3,9-11]. Recently, cryopreserved sporozoites administered
intradermally and intramuscularly, have also been success-
fully used to initiate infection [12-14]. While these CHMI
approaches are routinely used at a number of centres in
the USA, Netherlands, UK and Australia, the ability to im-
plement, maintain and use them is limited in part by ac-
cess to suitable material and this has been restricted by
technical considerations including access to insectary fa-
cilities to house and feed mosquitoes and to Plasmodium-
infected individuals.
Previous studies that have utilized a cell bank of Plas-
modium-infected erythrocytes to induce experimental
malaria infections have used parasitized erythrocytes
that were cryopreserved directly ex vivo from a parasi-
taemic volunteer who had been deliberately inoculated
by mosquitoes infected with P. falciparum 3D7 [15].
This material has been used in numerous studies with
diverse endpoints and has been administered to >200
volunteers [3,9,11]. More recently, a malaria cell bank was
collected from a returned traveller infected with P. vivax
and has been used to infect human volunteers [16]. These
studies, together with decades of experience with blood
transfusion and significant advances in the testing utilized
for detection of infection of donor blood with blood-
borne pathogens have helped to overcome many of the
ethical and safety concerns that were deemed to be associ-
ated with administering Plasmodium-infected erythrocytes
for CHMI [2].
While these cell banking methods represent obvious
ways to obtain suitable material for blood-stage CHMIs,
they rely on access to deliberately infected volunteers/
malaria-infected returned travellers and ethical approval
to collect, store and use this material. An ex vivo cell bank
is also a finite resource which will eventually be exhausted.Additionally, if the Plasmodium-infected donor is not of
the “universal” O Rh negative blood type, then this places
additional restrictions on the selection of potential recipi-
ents, limiting it to those with a compatible blood type.
An alternative approach for the production of a cell
bank of P. falciparum-infected erythrocytes is to exploit
the relatively straightforward methodology for the con-
tinuous in vitro culture of malaria parasites (for example
[17]) to generate a large quantity of Plasmodium-in-
fected erythrocytes that can then be cryopreserved to pro-
duce a cell bank. As this material is for clinical use,
production must follow current, local GMP regulatory re-
quirements and guidelines for investigational products.
This involves implementing a GMP environment suitable
for the manufacture of Investigational Medicinal Products
(Annex 13 of the Pharmaceutical Inspection Convention
and Pharmaceutical Inspection Co-operation Scheme
(PIC/S) Guide) which encompasses the establishment of
robust quality management systems and standard operat-
ing procedures, rigorous documentation to monitor and
control the manufacturing process and utilising accredited
contract research organizations to undertake the relevant
testing of the final product. Administration of this mater-
ial to human volunteers is also governed by regulatory and
ethical guidelines. However, this culture-based approach
has numerous advantages, including permitting the selec-
tion of the parasite strain and the blood type of the eryth-
rocytes used to propagate the parasite.
Three cultured malaria cell banks, consisting of Plasmo-
dium falciparum-infected erythrocytes, have been pro-
duced using GMP-grade, clinically isolated or research
(non-GMP)-grade parental cell lines as starting material.
Described below are the manufacturing process and
in vitro characterization of these P. falciparum blood-
stage malaria cell banks that is required to achieve ap-
proval for human use.
Methods
The manufacture and release of three Plasmodium fal-
ciparum blood-stage malaria cell banks, suitable for use
in CHMI studies, was undertaken at The Institute for
Glycomics, Griffith University, Australia (P. falciparum
NF54 and 7G8) and Q-Gen, QIMR Berghofer Medical
Research Institute (P. falciparum 3D7).
Malaria parasites
A vial of GMP-grade P. falciparum NF54 master cell
bank was provided by Sanaria Inc. [18]. This parasite
was originally isolated from a returned traveller, resident
in Amsterdam [19]. A vial of the same provenance, but
isolated from a subject with a sporozoite-induced infec-
tion [15] was used as the source of P. falciparum 3D7
parasites. A vial of research (non-GMP)-grade P. falcip-
arum 7G8 was provided by the Australian Army Malaria
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from the isolate IMTM 22, which originated in Brazil [20].
Culture of P. falciparum parasites for the production of
the blood-stage malaria cell banks
The culturing processes for producing the P. falciparum
NF54 and 7G8 cell banks were undertaken at Griffith
University whereas the production of the P. falciparum
3D7 bank was carried out at Q-Gen, QIMR Berghofer
Medical Research Institute. All of the processes were car-
ried out in compliance with the Annex 13, PIC/S Guide,
in cleanrooms and a monitored environment suitable for
production of sterile biologics in accordance with ap-
proved protocols.
Leukocyte-depleted O negative erythrocytes used dur-
ing the manufacturing process were supplied by Key
Biologics, LLC, Memphis, TN, USA for the P. falciparum
NF54 and P. falciparum 7G8 cell banks and the Australian
Red Cross Blood Service (ARCBS) for the P. falciparum
3D7 cell bank. Serum for parasite culture for all three
banks was supplied by Key Biologics. All of the materials
obtained from blood donors were compliant with the
US Federal Drug Administration (FDA) and Australian
Therapeutic Goods Administration (TGA) Order 88. The
donors of these materials had been screened for infectious
agents in compliance with applicable TGA and FDA regu-
lations, requirements and guidelines for blood screening
and blood collection. Additionally, donors were asked spe-
cific questions to ascertain the possibility of recent expos-
ure to the malaria parasite and anti-malarial antibody
testing was carried out on the blood components. Prior to
the use of these blood components in the manufacturing
process, aliquots of erythrocytes and serum were tested to
confirm that they could support the growth of the malaria
parasite.
The expansion and production of these blood-stage
malaria cell banks was carried out as previously published
[15]. Briefly, seed vials containing the P. falciparum NF54,
3D7 or 7G8 parasitized red blood cells in Glycerolyte 57
solution (Baxter) were retrieved from liquid nitrogen and
taken to the cleanroom for processing. The vial was placed
in a water bath at 37°C for 1–2 minutes until thawed.
Deglycerolization of the sample was performed as follows.
An equal volume of warmed 12% NaCl was added drop-
wise while gently shaking the tube. The mixture was
allowed to stand for 5 minutes at ambient temperature.
Following this, 9x the cell suspension volume of 1.6%
NaCl was added drop-wise while gently shaking the tube.
The tube was then centrifuged at 433 g for 5 minutes at
ambient temperature. Following removal of the super-
natant, 9x the original cell suspension volume of 0.9%
NaCl was added drop-wise while gently shaking the tube.
The tube was centrifuged again at 433 g for 5 minutes at
ambient temperature. The cell pellet was measured andhuman blood group O Rh negative erythrocytes were
added so that the total cell pellet was at a 5% haematocrit.
This cell pellet was then suspended in 6 ml of RPMI-1640
(Gibco) supplemented with 10% heat inactivated human
serum and 0.01 mg/ml gentamicin (Gibco). The cell sus-
pension was transferred to a tissue culture dish and was
placed in an Astec multi-gas incubator (5% O2, 5% CO2
and 90% N2) at 37°C. The parasites were then cultured as
described previously [17]. Parasite cultures were checked
regularly, at which time, thin blood films were made from
collected samples, stained with Diff Quik (Bacto Labora-
tories) and read to ascertain the parasitaemia. As required,
the parasites were sub-cultured to 0.5% parasitaemia with
freshly washed human erythrocytes to maintain a 5%
haematocrit and placed back in the multi-gas incubator.
This culturing process was continued with the number of
tissue culture dishes/flasks increasing until the malaria
parasite was at ring stage and it was calculated that there
was adequate material to cryopreserve for the cell bank.
Immediately prior to cryopreservation, thin blood films
were made to define the parasitaemia of the produced cell
banks. Slides were stained with Diff Quik and read 4 times
by 2 independent microscopists, counting a minimum of
1,000 cells for each read. The average of these 4 reads was
used to define the parasitaemia of the cell bank.
Cryopreservation of the P. falciparum blood-stage malaria
cell banks
To cryopreserve the ring stage parasitized erythrocytes for
a cell bank, the cell suspensions from the different flasks/
dishes were pooled and centrifuged at 433 g for 10 minutes.
Following removal of the supernatants, the resulting
cell pellets were pooled into a single flask and the total
pellet volume measured. Twice the cell pellet volume of
Glycerolyte 57 was added drop-wise while gently mixing
by shaking the flask. One millilitre of pRBC/Glycerolyte
57 suspension was placed in each labelled cryovial. Cryo-
vials were transported to a Planer Kryo 560–16 Controlled
Rate Freezer and were frozen according to the following
programme: 1°C decrease/minute until the temperature
reached −70°C, 10°C decrease/minute until the temperature
reached −180°C. Following completion of the freezing
programme, cryovials were transferred to liquid nitrogen
for long-term storage. A proportion of the cryovials were
either stored separately as retention samples to allow for
future retrospective analysis, if required or were allocated
for release testing of the cell banks according to specific
criteria (see Additional file 1).
Assessment of P. falciparum blood-stage malaria cell bank
parasite viability after thawing by tritiated hypoxanthine
uptake
Incorporation of 3[H]-hypoxanthine was performed as
previously described [21] with some modifications. Briefly,
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thawed, as outlined above, and immediately added in
quadruplicate to a 96-well flat bottom plate at 2% haem-
atocrit in RPMI-1640 (Gibco) supplemented with 10%
heat inactivated human serum and 0.01 mg/ml gentamicin
(Gibco). Non-parasitized human erythrocytes were added
to the plate as a control. Parasitized and non-parasitized
erythrocytes were incubated in the presence of 0.5 μCi/
well of 3[H]-hypoxanthine (Amersham Pharmacia) for up
to 36 hours. Plates were then placed at −80°C overnight.
Following thawing, cells were harvested onto glass fibre
mats (Perkin Elmer) using a Filtermate cell harvester
(Perkin Elmer) and 3[H]-hypoxanthine incorporation
was determined using a Microbeta2 Microplate Counter
(Perkin Elmer).
Assessment of the in vitro cloning efficiency of the
P. falciparum blood-stage malaria cell bank parasites by
PfHRPII production
Quantitative viability of the P. falciparum NF54 and 7G8
cell bank parasites was determined by measuring the clon-
ing efficiency via a limit dilution approach with positiv-
ity determined by production of PfHRPII. This was
undertaken using the SD Malaria Antigen P.f ELISA
kit (Standard Diagnostics), a sandwich enzyme-linked
immunosorbent assay for the qualitative detection of
P. falciparum histidine rich protein II (HRP-II).
A vial of the P. falciparum NF54 and 7G8 cell banks
were thawed, as outlined above. Cell pellets were re-
suspended in RPMI-1640 (Gibco) supplemented with
10% heat inactivated human serum and 0.01 mg/ml gen-
tamicin (Gibco). Based on the recorded parasitaemia of
the cell bank when it was cryopreserved, the cell bank
parasites were plated out in 96-well flat bottom plates at
2% haematocrit at theoretical concentrations of 40, 4, 2,
1, 0.5 parasites/well with 100 μl of parasite suspension
added/well. Each concentration was plated out in repli-
cates of 30 and non-parasitized erythrocytes were included
as a negative control. Plates were placed in an atmosphere
of 90% N2, 5% O2, 5% CO2, at 37°C for 7 days. On Day 4,
the media was removed from each well and replaced with
fresh media. On Day 7, plates were processed for detec-
tion of P. falciparum HRPII. The manufacturer’s instruc-
tions were followed, with minor modifications. Following
mixing, 50 μl of the parasite suspension from each well
was transferred to the corresponding well of an uncoated
microplate. Seventy-five microlitres of the working en-
zyme conjugate (anti-mouse Plasmodium falciparum
HRPII Ig conjugated to horseradish peroxidase in lysis
buffer) was then added into each well of the uncoated mi-
croplate. Plates were incubated at ambient temperature
for 30 minutes. One hundred microlitres was then trans-
ferred from each well of the uncoated microplate to the
corresponding well of the pre-coated microplate. Plateswere incubated at 37°C for 90 minutes. Following this,
plates were washed 6 times with the wash buffer and
100 μl of tetramethylbenzidine substrate was added to
each well. Plates were incubated at ambient temperature
for 10 minutes, after which 100 μl of a 1 N Hydrochloric
acid stop solution was added to stop the reaction. Plates
were read on an xMark microplate spectrophotometer
(Biorad) at 450 nm, with a reference wavelength of 620
nM. Detection of P. falciparum HRPII was used to define
a parasite positive well, with the cut-off for positivity cal-
culated as the mean + 3 standard deviations of the wells
containing normal erythrocytes alone. A limiting dilution
analysis was undertaken to determine the frequency of vi-
able parasites [22].
Sterility testing of P. falciparum blood-stage malaria cell
banks
Sterility testing for the assessment of bio-contamination
with aerobic and anaerobic microorganisms was under-
taken. For P. falciparum NF54 and 7G8, this was per-
formed by Biotest Laboratories Pty Ltd (Underwood,
Australia) using the direct inoculation technique into
tryptone soya broth and thioglycollate medium. For P.
falciparum 3D7, the BacT/ALERT® system (bioMerieux)
was employed, using a process that has been validated by
the ARCBS for detection of microorganisms in human
blood products. Test parameters and acceptance criteria
were defined according to the British Pharmacopoeia
2014, Appendix XVI A.
Mycoplasma testing of P. falciparum blood-stage malaria
cell banks
Mycoplasma testing was undertaken by ams Laboratories
Pty Ltd (Silverwater, Australia) (for P. falciparum NF54
and 7G8) or Q-Gen, QIMR Berghofer Medical Research
Institute (P. falciparum 3D7), using a PCR-based method.
The limit of sensitivity of the assay was 10 copies/ml.
Endotoxin testing of P. falciparum blood-stage malaria
cell banks
Endotoxin testing was undertaken by ams Laboratories
Pty Ltd (Silverwater, Australia) (for P. falciparum NF54
and 7G8) using a Kinetic Chromogenic LAL test and Biot-
est Laboratories (Underwood, Australia) (for P. falciparum
3D7) in accordance with the British Pharmacopoeia
Appendix XIV C. The detection limit of the assay was 0.5
or 0.06 Endotoxin Units (EU)/ml respectively.
Viral testing of the P. falciparum blood-stage malaria cell
banks
Viral testing of the initial P. falciparum NF54 master cell
bank vial provided by Sanaria was performed in compli-
ance with applicable FDA guidelines. As it was provided
as a GMP-grade parental cell line, and blood components
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tion of the cell bank, the Griffith University P. falciparum
NF54 cell bank was not re-tested.
Viral testing of the cultured P. falciparum 7G8 bank
was performed by Charles River Pharmaceutical Services
GmbH (Germany) and was undertaken in compliance
with applicable TGA guidelines. RT-PCR assays for
HAV (Hepatitis A virus), HBV (Hepatitis B virus), HCV
(Hepatitis C virus), HHV-6 (Human Herpes Virus 6), HHV-7
(Human Herpes Virus 7), HHV-8 (Human Herpes Virus 8),
HIV-1 (Human Immunodeficiency Virus 1), HIV-2 (Human
Immunodeficiency Virus 2), HTLV-I (Human T cell Lym-
photropic Virus 1), HTLV-II (Human T cell Lymphotropic
Virus 2), SV40 (Simian virus 40), EBV (Epstein Barr
Virus), CMV (Cytomegalovirus) and Parvovirus B19 and
PCR assays for Treponema paraluiscuniculi and T. palla-
dium were performed.
The clinically isolated P. falciparum 3D7 parental cell
bank was derived from blood collected from a donor
that had been infected with malaria through the bites of
infected mosquitoes under controlled conditions [15].
The donor was screened extensively for blood borne vi-
ruses prior to infection and then re-screened 12 months
following blood collection and had no evidence of blood
borne infections at these time points. Moreover, this P.
falciparum 3D7 parental cell bank has been directly in-
oculated into >200 human volunteers with pre-and post-
inoculation testing not showing any evidence of serocon-
version to adventitious viruses. The blood components
used in the culturing process were also obtained from
screened donors. Therefore, the risk for presence of blood
borne viruses in the P. falciparum 3D7 bank was deemed
to be minimal, and it was not retested.
Identity testing of the P. falciparum cell bank parasites
Identity testing was performed by Sanaria on the original
Sanaria GMP-grade P. falciparum NF54 cell bank that
was used as the starting material for the Griffith Univer-
sity cell bank. As this was provided as a GMP-grade
starting seed vial, further identity testing of the Griffith
University P. falciparum NF54 cell bank parasites was
not undertaken. Identity testing performed by Sanaria
was according to published methods and consisted of
typing the malaria parasites based on a polymorphic
microsatellite (PfRRM) within a known multicopy PfRR
repetitive element of P. falciparum [23,24]. The resulting
band pattern was matched to that of the reference stand-
ard isolate.
Identity testing was performed on the clinically iso-
lated P. falciparum 3D7 parental cell bank that was used
as the starting material for the P. falciparum 3D7 bank.
It was performed by DNA sequence analysis of three
polymorphic genes (msp1, msp2 and glurp), which veri-
fied sequence identity to the reference P. falciparum3D7 strain. Therefore, identity testing of the P. falcip-
arum 3D7 cell bank parasites was not undertaken.
Identity testing of the P. falciparum 7G8 cell bank was
undertaken by Griffith University in accordance with ap-
proved procedures as the starting seed bank material pro-
vided was research-grade. An MSP1 genotyping assay was
undertaken according to published methods, using the
R033 primers for the nested reaction [25]. The MSP1
nested amplicons were sequenced by the Australian Gen-
ome Research Facility Ltd and this was evaluated against
that of the P. falciparum 7G8 reference standard isolate.
In vitro anti-malaria drug susceptibility of the
P. falciparum blood-stage malaria cell bank parasites
Anti-malaria drug testing was performed on the P. falcip-
arum NF54 and 7G8 cell banks due to possible concerns
that the drug resistance phenotype of the parasite may have
altered following culture. Testing was performed at the
Army Malaria Institute, Enoggera, Queensland, Australia.
The ten anti-malaria compounds used were: artemether
(WWARN), artesunate (WWARN), atovaquone (Sigma),
chloroquine (Sigma), dihydroartemisinin (DKPHarm,Vietnam),
lumefantrine (WWARN), mefloquine (Sigma), proguanil
(Jacobus Pharmaceutical Company, Inc.), piperaquine
(WWARN) and pyrimethamine (WRAIR). One hundred
percent methanol was used to prepare the stock solution
of DHA, 50% methanol was used for artemether, chloro-
quine and piperaquine, whereas the rest of the com-
pounds were dissolved in DMSO.
Plasmodium falciparum 7G8 and NF54 cell bank para-
sites were placed in continuous culture in RPMI-1640-
LPLF (Gibco, Invitrogen Corporation, CA), supplemented
with 5.97 g/L HEPES buffer, 2.0 g/L D-glucose, 0.05 g/L
hypoxanthine, 40 mg/L gentamycin, 0.21% sodium bicar-
bonate (added fresh) and containing 10% human plasma
and 4% O(+) red blood cells in an atmosphere of 90% N2,
5% O2, 5% CO2, at 37°C as described previously [17]. Plas-
modium falciparum D6 was tested in parallel to the P. fal-
ciparum NF54 cell bank parasites, due to its’ known drug
sensitivity profile. Cultures were routinely synchronized
using D-sorbitol [21], when the majority of parasites
(>85%) were at early trophozoite (ring) stage.
The in vitro anti-malaria activities of 10 compounds
were assessed using the [3H]-hypoxanthine growth inhib-
ition assay [21]. Briefly, synchronized parasite cultures
(>90% rings, 4–8 hours post invasion in culture medium
lacking hypoxanthine) with a starting parasitaemia of 1%
and at 2% haematocrit, were exposed to the compounds
at 10 two-fold concentrations in 96-well plates (100 μl per
well). Uninfected red blood cells at 2% haematocrit were
used as background controls. The plates were incubated
in the gas mixture at 37°C. For all but two antifolate com-
pounds, proguanil and pyrimethamine, the assay duration
was 48 hours with [3H]-hypoxanthine (0.2 μCi/well) added
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of the experiment. For proguanil and pyrimethamine as-
says, the initial parasitaemia was 0.5% and parasite cul-
tures were exposed to the compounds for 96 hours with
[3H]-hypoxanthine added after the first 48 hours.
Following incubation, plates were frozen, then subse-
quently thawed and harvested using Tomtech Harvester
96 Mach II and radioactive counts were obtained using
Wallac TriLux 1450 Microbeta Liquid Scintillation Counter
(Perkin Elmer, USA). All assays were performed in tripli-
cate. For each compound, the data from at least two inde-
pendent experiments were obtained and analysed using
Graph Prism Software (GraphPad Prism V5.0, GraphPad
Software, Inc., CA). Drug concentration values were trans-
formed into logarithmic values. After subtracting the back-
ground values, the data from drug-treated wells were
normalized against drug-free control wells. Non-linear re-
gression analysis was carried out on the log values of the
compound’s concentration vs parasitic hypoxanthine in-
corporation to determine inhibitory concentrations. The
in vitro anti-malarial activity of the compound was defined
as inhibitory concentrations (IC50) and (IC90) that cause
50% and 90% inhibition of parasite growth.
Testing of the P. falciparum 3D7 cell bank parasites was
performed using similar methodology with minor modifica-
tions. The anti-malaria compounds used were: amodiaquine,
artemisinin, chloroquine, dihydroartemisinin, mefloquine,
pyronaridine, quinine and sulphadoxine.
Results
Evaluation of the parasitaemia of the P. falciparum cell
banks
Thin blood smears that had been prepared from the
P. falciparum cell banks immediately prior to cryopreser-
vation were examined and read to define the parasite
stages present and the parasitaemia of the cell banks. The
P. falciparum NF54 cell bank contained 80% of parasites
at ring stage with a 4.5% ring stage parasitaemia. The
P. falciparum 7G8 cell bank contained 78% of parasites at
ring stage with a 1.4% ring stage parasitaemia. Similarly,
the P. falciparum 3D7 bank contained 80% of parasites at
ring stage with a 3% ring stage parasitaemia.
Confirmation of the identity of the P. falciparum cell bank
parasites
The Griffith University P. falciparum NF54 cell bank
and the P. falciparum 3D7 cell bank were not tested to
confirm their identity as the parental cell banks, from
which they were derived, have a well characterized prov-
enance and were manufactured in a cleanroom environ-
ment. Thus, the possibility of cross-contamination with
another malaria parasite was considered negligible.
Genotyping was undertaken on the Griffith University
P. falciparum 7G8 cell bank to confirm its identity, as itwas derived from research-grade material. Following a
primary amplification of the block 2 region of MSP1, a
nested reaction using the R033 allelic type-specific primers
was performed. Analysis of the sequence data for the nested
amplicon revealed 100% identity between the Griffith
University P. falciparum 7G8 cell bank parasites and
the P. falciparum 7G8 reference strain.Evaluation of the viability of the P. falciparum cell bank
parasites
Following thawing of the cell bank vials, the viability of
the cell bank parasites was assessed in 3 ways. For all three
cell banks, blood smears were prepared from cultures on
the day of thawing and days 1–3 following initiation of cul-
ture. Growth of the cell bank parasites, indicating viability,
was confirmed by regular microscopy of the cultures. Pas-
sage of the parasites into subsequent asexual cycles was
demonstrated by confirming the appearance of the ring
stage parasites in significantly increased numbers.
For the P. falciparum NF54 and 7G8 cell bank parasites,
viability was also assessed by incorporation of [3H]-
hypoxanthine into newly synthesized parasitic DNA.
Radioisotope uptake was demonstrated for the parasites in
these P. falciparum cell banks, in comparison with the
non-parasitized erythrocyte control (Figure 1).
Finally, for the P. falciparum NF54 and 7G8 cell bank
parasites, the percentage of viable parasites in the cell
banks was derived from a limiting dilution assay [22], in
which the frequency of viable, parasitized cells was de-
termined by limit dilution analysis with positivity deter-
mined by production of P. falciparum HRPII. The cell
dose yielding 37% negative wells was determined by
interpolation and this was used to estimate the frequency
of responding cells in each of the malaria cell banks. Thus,
the number of responding cells in the P. falciparum 7G8
bank was estimated at approximately 1:6 (Figure 2), equat-
ing to an approximate 15% viability of malaria parasites in
this bank. The number of responding cells in the P. falcip-
arum NF54 cell bank was estimated at approximately 1:2
(Figure 2), which equates to an approximate 50% viability
of malaria parasites in this bank.Detection of mycoplasma in the P. falciparum cell banks
There was no evidence of mycoplasma contamination in
any of the three expanded P. falciparum cell banks.Sterility testing and measurement of endotoxin in the
P. falciparum cell banks
Following a 14 day incubation period, there was no evi-
dence of growth of aerobic or anaerobic microorganisms.
The endotoxin testing revealed <0.500 EU/ml in each of
the produced cell banks.
Figure 1 Uptake of [3H]-hypoxanthine by A. P. falciparum NF54 and B. P. falciparum 7G8 cell bank parasites. Each treatment was tested
in quadruplicate; columns represent the mean + SE. pRBC: parasitized red blood cells, nRBC: normal red blood cells.
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banks
Viral testing of the original Sanaria P. falciparum NF54
cell bank was undertaken to comply with and satisfy applic-
able FDA guidelines. The Griffith University P. falciparumFigure 2 Graphical representation of limiting dilution analysis
results according to a single-hit Poisson model. Data are from
HRPII assays performed on A. P. falciparum 7G8 and B. P. falciparum
NF54 cell bank parasites. Positivity was determined based on
HRPII production.NF54 cell bank and the P. falciparum 3D7 cell bank were
not tested as they were derived from defined parental cell
banks and were manufactured using blood components
that had been screened for infectious agents in compliance
with applicable TGA, FDA and ARCBS regulations, re-
quirements and guidelines.
As the P. falciparum 7G8 cell bank was derived from
research-grade material, viral testing was undertaken to
exclude the presence of adventitious agents that may have
been present in this starting material and was undertaken
to comply with applicable TGA guidelines. Viral testing of
the P. falciparum 7G8 cell bank demonstrated that it was
negative for all agents that were tested for ie HAV, HBV,
HCV, HHV-6, HHV-7, HHV-8, HIV-1, HIV-2, HTLV-I,
HTLV-II, SV40, EBV, CMV, Human Parvovirus B19,
Treponema paraluiscuniculi and T. palladium.
Evaluation of the in vitro susceptibility of the
P. falciparum cell bank parasites to anti-malaria
compounds
The in vitro anti-malaria activities (expressed as IC50
and IC90 values) of the 10 compounds evaluated against
the P. falciparum NF54 and 7G8 cell bank parasites are
shown in Tables 1 and 2 respectively. P. falciparum D6
was tested as a reference strain, in parallel to P. falcip-
arum NF54, due to its known drug sensitivity profile
[26]. Similar to the drug-sensitive P. falciparum D6 line
(Additional file 2), P. falciparum NF54 cell bank para-
sites were sensitive to all anti-malaria compounds tested
(Table 1). P. falciparum 7G8 cell bank parasites were
susceptible to all the tested artemisinin derivatives (arte-
mether, artesunate and dihydroartemisinin) as well as to
atovaquone, mefloquine and lumefantrine (Table 2). It
was resistant to chloroquine, proguanil and pyrimeth-
amine and had a decreased susceptibility to piperaquine.
The P. falciparum 3D7 cell bank parasites were suscep-
tible to all of the eight anti-malaria compounds that
were tested (Additional file 3).




IC50 (nM) IC90 (nM)
Average (n = 2) Standard deviation (n = 2) Average (n = 2) Standard deviation (n = 2)
Artemether 50 5.9 1.7 9.9 2.4
Artesunate 50 3.3 0.2 6.0 0.4
Dihydroartemisinin 35 2.5 0.1 5.0 0.6
Atovaquone 25 0.22 0.06 1.3 0.5
Mefloquine 728 45 6 85 13
Piperaquine 200 19 6 28 9
Lumefantrine 800 118 14 318 166
Chloroquine 250 11.2 1.4 14.7 2.0
Pyrimethamine 50 0.57 0.04 1.28 0.15
Proguanil 200,000 292 20 1,335 504
Stanisic et al. Malaria Journal  (2015) 14:143 Page 8 of 10Quality review of the P. falciparum blood-stage malaria
cell banks
Following testing of the cell banks according to the cri-
teria listed in Additional file 1, a quality review was under-
taken to establish whether the P. falciparum cell banks
were suitable for release and eventual administration to
human volunteers in accordance with annex 13 of the
PIC/S Guide and relevant guidelines. All documentation
associated with the manufacture of the cell banks and the
results of the testing outlined in Additional file 1 were
reviewed and met with the established test criteria. The
P. falciparum NF54, 3D7 and 7G8 cell banks were deemed
to pass the required criteria for release.
Discussion
The aim of the present study was to establish method-
ology for the production of GMP-grade, cultured malaria
cell banks, as a new approach for producing material





Average (n = 2) Standa
Artemether 50 5.5 2.5
Artesunate 50 2.5 0.3
DHA 50 2.6 0.7
Atovaquone 400 2.1 0.3
Mefloquine 200 11.9 0.5
Piperaquine 200 46 9
Lumefantrine 200 34 4
Chloroquine 1,000 130 6
Pyrimethamine 5,000 2,799 52
Proguanil 200,000 5,677 617studies to evaluate anti-malaria drugs and malaria vaccine
candidates. Three blood-stage malaria cell banks, derived
from three different starting materials (GMP-grade P. fal-
ciparum NF54 used to produce PfSPZ Vaccine [5,18,27]
and PfSPZ Challenge [12-14], clinically isolated P. falcip-
arum 3D7 [15] and research (non-GMP)-grade P. falcip-
arum 7G8) were manufactured in cleanrooms suitable for
the production of sterile products using screened blood
components utilising robust standard operating proce-
dures. The cell banks were subsequently tested according
to specific criteria and as required by local guidelines of
the Australian TGA, and the results evaluated to deter-
mine whether the cell banks could be released for subse-
quent use in clinical malaria studies.
All of the in vivo expanded cell banks were shown to
contain viable parasites. The quantification of viable par-
asites (as was calculated for the P. falciparum 3D7 and
7G8 cell banks), together with the parasitaemia of the
cells banks immediately prior to cryopreservation, canti-malaria compounds against the P. falciparum 7G8 cell
IC90 (nM)
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sion that is required to deliver a defined dose of viable
parasites in clinical studies.
Sterility and endotoxin testing, performed using vali-
dated techniques, demonstrated that all cell banks were
negative for bacterial contamination. Similarly, all three
cell banks were tested to comply with applicable region-
specific regulations and guidelines and were demonstrated
to be free of contamination with mycoplasma and the do-
nors of the erythrocytes and serum were shown to be
negative for a broad panel of viral agents. One of the pro-
duced banks (P. falciparum 7G8) was tested by PCR for
blood borne viruses and was negative for all tested agents.
This gives confidence in the biosafety of the product itself
i.e. that when administered to human volunteers they will
not result in an unintended infection with any of the
tested adventitious agents.
Establishing the in vitro susceptibility of the P. falcip-
arum parasites in the cell banks to a panel of anti-
malaria compounds is a critical step in ensuring that the
cell banks can be safely administered to human volun-
teers. These data inform selection of the anti-malaria
medication that will be administered to human volunteers
who have received the cell bank parasites, to ensure
complete resolution of the malaria infection. The P. falcip-
arum NF54 parasites were susceptible to all drugs tested.
Subjects infected with P. falciparum NF54 parasite have
been successfully treated with chloroquine, atovaquone/
proguanil (Malarone®) and with artemether/lumefantrine
(known as Coartem® or Riamet®) [12,13,28,29], and all
would be appropriate treatment. The P. falciparum 7G8
parasites exhibited resistance to a number of the drugs
tested, restricting the treatment options. Only mefloquine
(Lariam®) has been used to treat this parasite in clinical trials
[29,30]. However, artemether/lumefantrine would undoubt-
edly be effective. The parasite has reduced susceptibility to
proguanil as compared to P. falciparum NF54, but is highly
susceptible to atovaquone, so atovaquone/proguanil may
be effective also. The P. falciparum 3D7 parasites demon-
strated susceptibility to all compounds tested, so all would
be appropriate treatment.
One of the advantages of this culture-based approach to
generating a P. falciparum malaria cell bank is the ability
to select the parasite strain. Currently, few P. falciparum
strains are available with which to evaluate the strain-
transcending nature of the immune response induced by
vaccine candidates, prior to larger and more expensive
field-based trials in malaria-exposed individuals. Strain or
allele-specific immune responses induced by sub-unit vac-
cine candidates may have contributed to the disappointing
efficacy observed thus far, when vaccine candidates have
been evaluated in a field setting. The selection of numer-
ous, defined parasite strains for the early evaluation of vac-
cine candidates will ensure that only the most promisingare channelled into the more expensive field-based trials
for evaluation of efficacy.
An important aspect of this culture-based approach is
the possibility to take research-grade material through to
a final, GMP-grade product. Thus, the lack of access to
GMP-grade starting material will not impose restrictions
on the selection of parasite strains for a cultured cell
bank. While the conversion of research-grade material to
GMP-grade is an unexplored approach for clinical malaria
research, there is precedence for this in clinical stem cell
research [31]. It involves the transfer of research (non-
GMP)-grade material to a cleanroom suitable for produc-
tion of sterile products, where it is further cultured using
defined, GMP-quality reagents according to robust stand-
ard operating procedures. Rigorous testing must be under-
taken on the final product to determine that it is suitable
for release and administration to humans and should
comply with the current, local GMP requirements. This
testing will ensure that there is no biological contamination
and will exclude the possibility that adventitious agents
may have been present in the research-grade material
prior to culture in the cleanroom.
Following the successful in vitro characterization and
release of these P. falciparum blood-stage malaria cell
banks in these current studies, future work will entail the
characterization of these cell banks in vivo. As a result of
these processes, the necessary regulatory and ethical clear-
ances have been obtained to examine the infectivity of
these cell banks in malaria-naïve human volunteers, as has
been previously undertaken for non-cultured P. falcip-
arum and P. vivax cell banks that have been derived from
malaria infected volunteers [9,15,16].
Conclusions
The current study describes the first alternate method-
ology for the production of blood-stage malaria cell banks
for use in controlled human malaria infections in CHMI
studies. The ability to undertake these studies is critical for
advancing the development of a malaria vaccine and novel
anti-malaria drugs. Unlike existing published methods, this
alternate method is culture-based and is not restricted by
access to volunteers who have been deliberately infected
with malaria or who contracted malaria infection following
travel to/residence in a malaria endemic area.Additional files
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